PHILADELPHIA -- Treatment with 177Lu-Dotatate (Lutathera) offered a quality of life (QoL) benefit to patients with midgut neuroendocrine tumors, researchers said here. Compared with patients on a high ...

TAMPA, Fla. - Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the ...

Please provide your email address to receive an email when new articles are posted on . Treatment with 177 Lutetium-DOTATE appeared to improve the overall response rate and prolonged PFS compared with ...

The multitargeted tyrosine kinase inhibitor (TKI) lenvatinib induced a strong tumor response in patients with previously treated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), ...

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells There are few effective therapies for pancreatic neuroendocrine tumors ...

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated ...

Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced gastrointestinal NETs. The phase 3 CABINET trial demonstrated that Cabometyx ...

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial Patients with jejunal and ileocecal NETs who were treated at the Moffitt Cancer Center ...

The approval last week of a novel radiaopharmaceutical to treat a group of rare cancers provides a new option for patients with these malignancies. The product, 177 Lu-dotatate (Lutathera, Advanced ...